Axogen

AXGN

----

Current ValuationThe current P/E ratio is -63.26, above the reasonable range, cheaper than 0.77% of the time in the past 1 years, and the industry ranks 154/173, the industry Median -0.92.

-63.26xP/E

Stock price$36.17Earnings per share$-0.57

Historical Valuation

P/E ratioTypical rangeMedian

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.

012243648

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.

0x30x60x90x120x150x

P/E ratio
Name/Symbol
BAXUSBaxter	-12.11x	141.71%	$12.87B
GKOSUSGlaukos	-51.91x	75.37%	$9.76B
TFXUSTeleflex	-5.11x	118.39%	$5.27B
IRTCUSIRhythm	-254.57x	70.88%	$3.55B
PLSEUSPulse Biosciences	-43.24x	26.85%	$3.46B
BFLYUSButterfly Network	-28.82x	31.45%	$2.16B
AXGNUSAxogen	-63.26x	15.29%	$2.12B
ASSTUSStrive	-1.96x	63.23%	$1.91B
ATECUSAlphatec	-15.19x	41.67%	$1.67B
NVCRUSNovocure	-11.21x	1.23%	$1.67B
KMTSUSKestra Medical Tech	-10.55x	0.94%	$1.58B
DRTSUSAlpha Tau Medical	-13.70x	--	$1.27B
TNDMUSTandem Diabetes	-18.30x	77.60%	$1.16B
ENOVUSEnovis	-0.99x	100.97%	$1.10B
PRCTUSPROCEPT BioRobotics	-9.97x	3.47%	$1.09B
IARTUSIntegra LifeSciences	-148.84x	109.42%	$1.08B
AORTUSArtivion	-326.37x	266.67%	$1.04B
CBLLUSCeribell	-15.20x	35.15%	$1.00B
QDELUSQuidelOrtho	-0.92x	75.33%	$966.91M
BBNXUSBeta Bionics	-12.76x	11.45%	$931.23M

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.